Foundations Investment Advisors LLC Has $2.33 Million Holdings in Abbott Laboratories $ABT

Foundations Investment Advisors LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 60.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,429 shares of the healthcare product maker’s stock after purchasing an additional 6,588 shares during the period. Foundations Investment Advisors LLC’s holdings in Abbott Laboratories were worth $2,334,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Paulson Wealth Management Inc. grew its holdings in shares of Abbott Laboratories by 21.2% during the third quarter. Paulson Wealth Management Inc. now owns 2,422 shares of the healthcare product maker’s stock worth $324,000 after purchasing an additional 423 shares during the last quarter. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the 3rd quarter worth about $29,000. AE Wealth Management LLC grew its holdings in Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares during the last quarter. Private Wealth Asset Management LLC increased its position in Abbott Laboratories by 14.1% in the 3rd quarter. Private Wealth Asset Management LLC now owns 12,955 shares of the healthcare product maker’s stock valued at $1,735,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Great Lakes Advisors LLC raised its stake in shares of Abbott Laboratories by 3.7% in the third quarter. Great Lakes Advisors LLC now owns 1,342,628 shares of the healthcare product maker’s stock worth $179,832,000 after acquiring an additional 48,450 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock has a market cap of $190.08 billion, a price-to-earnings ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72. The business has a 50 day simple moving average of $122.77 and a 200 day simple moving average of $127.49. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wells Fargo & Company increased their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Evercore ISI dropped their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, Benchmark initiated coverage on Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $140.75.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.